Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors

Kord M. Kober, Melissa Mazor, Gary Abrams, Adam Olshen, Yvette P. Conley, Marilyn Hammer, Mark Schumacher, Margaret Chesney, Betty Smoot, Judy Mastick, Steven M. Paul, Jon D. Levine, Christine Miaskowski

Research output: Contribution to journalArticle

Abstract

Context: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors. Objectives: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN. Methods: Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN. Results: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning. Conclusion: The findings from this large descriptive study are the first to document the impact of PIPN on survivors’ symptom burden, functional status, and QOL.

Original languageEnglish (US)
JournalJournal of Pain and Symptom Management
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Peripheral Nervous System Diseases
Paclitaxel
Survivors
Neoplasms
Quality of Life
Upper Extremity
Pain
Touch
Ovarian Neoplasms
Comorbidity
Lower Extremity
Lung Neoplasms
Body Mass Index
Demography

Keywords

  • balance
  • cancer
  • chemotherapy
  • Paclitaxel
  • pain
  • peripheral neuropathy
  • quality of life
  • stress
  • survivor

ASJC Scopus subject areas

  • Nursing(all)
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors. / Kober, Kord M.; Mazor, Melissa; Abrams, Gary; Olshen, Adam; Conley, Yvette P.; Hammer, Marilyn; Schumacher, Mark; Chesney, Margaret; Smoot, Betty; Mastick, Judy; Paul, Steven M.; Levine, Jon D.; Miaskowski, Christine.

In: Journal of Pain and Symptom Management, 01.01.2018.

Research output: Contribution to journalArticle

Kober, KM, Mazor, M, Abrams, G, Olshen, A, Conley, YP, Hammer, M, Schumacher, M, Chesney, M, Smoot, B, Mastick, J, Paul, SM, Levine, JD & Miaskowski, C 2018, 'Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors', Journal of Pain and Symptom Management. https://doi.org/10.1016/j.jpainsymman.2018.08.017
Kober, Kord M. ; Mazor, Melissa ; Abrams, Gary ; Olshen, Adam ; Conley, Yvette P. ; Hammer, Marilyn ; Schumacher, Mark ; Chesney, Margaret ; Smoot, Betty ; Mastick, Judy ; Paul, Steven M. ; Levine, Jon D. ; Miaskowski, Christine. / Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors. In: Journal of Pain and Symptom Management. 2018.
@article{59f85967cdc1428cb53cc864265a23ec,
title = "Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors",
abstract = "Context: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors. Objectives: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN. Methods: Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN. Results: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning. Conclusion: The findings from this large descriptive study are the first to document the impact of PIPN on survivors’ symptom burden, functional status, and QOL.",
keywords = "balance, cancer, chemotherapy, Paclitaxel, pain, peripheral neuropathy, quality of life, stress, survivor",
author = "Kober, {Kord M.} and Melissa Mazor and Gary Abrams and Adam Olshen and Conley, {Yvette P.} and Marilyn Hammer and Mark Schumacher and Margaret Chesney and Betty Smoot and Judy Mastick and Paul, {Steven M.} and Levine, {Jon D.} and Christine Miaskowski",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jpainsymman.2018.08.017",
language = "English (US)",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors

AU - Kober, Kord M.

AU - Mazor, Melissa

AU - Abrams, Gary

AU - Olshen, Adam

AU - Conley, Yvette P.

AU - Hammer, Marilyn

AU - Schumacher, Mark

AU - Chesney, Margaret

AU - Smoot, Betty

AU - Mastick, Judy

AU - Paul, Steven M.

AU - Levine, Jon D.

AU - Miaskowski, Christine

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Context: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors. Objectives: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN. Methods: Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN. Results: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning. Conclusion: The findings from this large descriptive study are the first to document the impact of PIPN on survivors’ symptom burden, functional status, and QOL.

AB - Context: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors. Objectives: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN. Methods: Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN. Results: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning. Conclusion: The findings from this large descriptive study are the first to document the impact of PIPN on survivors’ symptom burden, functional status, and QOL.

KW - balance

KW - cancer

KW - chemotherapy

KW - Paclitaxel

KW - pain

KW - peripheral neuropathy

KW - quality of life

KW - stress

KW - survivor

UR - http://www.scopus.com/inward/record.url?scp=85054165306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054165306&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2018.08.017

DO - 10.1016/j.jpainsymman.2018.08.017

M3 - Article

C2 - 30172061

AN - SCOPUS:85054165306

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

ER -